Controversial issues of type 2 myocardial infarction patients management
https://doi.org/10.17802/2306-1278-2022-11-1-78-89
Abstract
Highlights. The article presents relevant literary data on the epidemiology, main causes, approaches to the diagnostics and treatment of type 2 myocardial infarction patients. The authors emphasize an unfavorable prognosis in these patients due to comorbidity that leads to development of myocardial infarction. They highlight the need to improve and unify approaches to identifying this phenomenon, as well as the necessity to conduct observational and randomized studies to evaluate approaches to the treatment of type 2 myocardial infarction patients.
Abstract. The article summarizes the available data from clinical trials and current guidelines, approaches to the definition and type 2 myocardial infarction (MI) differential diagnosis in clinical practice. The attention is focused on the fundamental difference between type 1 and type 2 MI and the need to consider the comorbidities for the identification of etiological factors type 2 MI development. The lack of evidencebased medical data regarding the prognosis and effective treatment of patients with type 2 MI is emphasized. Nevertheless, such patients are characterized with high rates of overall and cardiovascular mortality in hospital and long-term disease course, as well as a high rate of readmission. Thus, there is the need for multicenter observational studies of type 2 MI patients and the development of algorithms for treatment and rehabilitation of this category of patients.
About the Authors
V. I. Kinash
Budgetary Institution of the Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Dispensary” of the Center for Diagnosis and Cardiovascular Surgery”
Russian Federation
Competing Interests:
Russian Federation
Vladimir I. Kinash - X-ray Endovascular Surgeon, Budgetary Institution of Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Hospital” of the Diagnostic and Cardiovascular Surgery Center”; graduate student at the Department of Cardiology, Budgetary Institution of Higher Education, Khanty-Mansiysk Autonomous Okrug - Ugra, “Surgut State University”.
69/1, Lenina Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628416.
Competing Interests:
No
A. S. Vorobev
Budgetary Institution of the Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Dispensary” of the Center for Diagnosis and Cardiovascular Surgery”; Surgut State University
Russian Federation
Competing Interests:
Russian Federation
Anton S. Vorobiev - PhD, Associate Professor Cardiologist, Budgetary Institution of Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Hospital” of the Diagnostic and Cardiovascular Surgery Center”; Associate Professor at the Cardiology Department, Senior Research Assistant at the Scientific Educational Center, Surgut State Medical Institute of Higher Education, Khanty-Mansiysk Autonomous Okrug - Ugra, “Surgut State University”.
69/1, Lenina Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628416; 1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628412.
Competing Interests:
No
I. A. Urvantseva
Budgetary Institution of the Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Dispensary” of the Center for Diagnosis and Cardiovascular Surgery”; Surgut State University
Russian Federation
Competing Interests:
Russian Federation
Irina A. Urvantseva - PhD, Associate Professor, Head Doctor, Budgetary Institution of Khanty-Mansiysk Autonomous Okrug - Ugra “District Cardiology Hospital” of the Diagnostic and Cardiovascular Surgery Center”; Head of the Cardiology Department, Surgut State University.
69/1, Lenina Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628416; 1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628412.
Competing Interests:
No
L. V. Kovalenko
Surgut State University
Russian Federation
Competing Interests:
Russian Federation
Lyudmila V. Kovalenko - PhD, Professor, Head of the Medical Institute, Head of the Department of Pathophysiology and General Pathology, Budgetary Institution of Khanty-Mansiysk Autonomous Okrug - Ugra “Surgut State University”.
1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug - Ugra, 628412.
Competing Interests:
No
V. V. Kashtalap
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”; Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Vasily V. Kashtalap - PhD, Associate Professor, Head of Clinical Cardiology Department, Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”; Professor at the Department of Cardiology and Cardiovascular Surgery of Federal State Budgetary Educational Institution of Higher Education "Kemerovo State Medical University" the Ministry of Health of the Russian Federation.
6, Sosnoviy blvd., Kemerovo, 650002; Voroshilova Street, 22a, Kemerovo, 650000.
Competing Interests:
В.В. Кашталап входит в редакционную коллегию журнала «Комплексные проблемы сердечно-сосудистых заболеваний»
References
1. Ministry of health Russian Federation. The incidence rate of adult population of Russia - 2018: Statistical materials (Zabolevaemost vzroslogo naseleniya Rossii- 2018: Statisticheskii sbornik (in Russian) Available at: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2018-god. (accessed 19.01.2022)
2. Townsend N., Wilson L., Bhatnagar P., Wickramasinghe K., Rayner M., Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232-3245. doi: 10.1093/eurheartj/ehw334..
3. DeFilippis A.P., Chapman A.R., Mills N.L., de Lemos J.A., Arbab-Zadeh A., Newby L.K., Morrow D.A. Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury. Circulation. 2019; 140 (20): 1661-1678. doi: 10.1161/CIRCULATIONAHA.119.040631.
4. Andreenko E.Yu., Yavelov I.S., Loukianov M.M., Vernohaeva A.N., Drapkina O.M., Boytsov S.A. Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem. Prevalence and Cardio-Vascular Risk Factors. Kardiologiia. 2018;58(10):53-58. (In Russ.) https://doi.org/10.18087/cardio.2018.10.10184
5. Nestelberger T., Boeddinghaus J., Badertscher P., Twerenbold R., Wildi K., Breitenbucher D., Sabti Z., Puelacher C., Rubini Gimenez M., Kozhuharov N., Strebel I., Sazgary L., Schneider D., Jann J., du Fay de Lavallaz J., Miro O., Martin-Sanchez F.J., Morawiec B., Kawecki D., Muzyk P., Keller D.I., Geigy N., Osswald S., Reichlin T., Mueller C.; APACE Investigators. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction. Journal of American College of Cardiology. 2017; 70 (13): 1558-1568. doi: 10.1016/j.jacc.2017.07.774.
6. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D.; Executive Group on behalf of the Joint European Society of Cardiology (ESC) / American College of Cardiology (ACC) / American Heart Association (AHA) /World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018; 138 (20): e618-e651. doi: 10.1161/CIR.0000000000000617.
7. Sandoval Y., Smith S.W., Sexter A., Schulz K., Apple F.S. Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury. European Heart Journal: Acute Cardiovascular Care. 2020; 9 (1): 62-69. doi: 10.1177/2048872618787796.
8. Smilowitz N.R., Subramanyam P., Gianos E., Reynolds H.R., Shah B., Sedlis S.P. Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction. Coronary Artery Diseases. 2018; 29 (1): 46-52. doi:10.1097/MCA.0000000000000545.
9. Meigher S., Thode H.C., Peacock W.F., Bock J.L., Gruberg L., Singer A.J. Causes of Elevated Cardiac Troponins in the Emergency Department and Their Associated Mortality. Academic Emergency Medicine. 2016; 23 (11): 1267-1273. doi: 10.1111/acem.13033.
10. Sarkisian L., Saaby L., Poulsen T.S., Gerke O., Jangaard N., Hosbond S., Diederichsen A.C., Thygesen K., Mickley H. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Non-elevated Troponins. American Journal of Medicine. 2016; 129 (4): 446. e5-446.e21. doi: 10.1016/j.amjmed.2015.11.006.
11. Javed U., Aftab W., Ambrose J.A., Wessel R.J., Mouanoutoua M., Huang G., Barua R.S., Weilert M., Sy F., Thatai D. Frequency of elevated troponin I and diagnosis of acute myocardial infarction. American Journal of Cardiology. 2009; 104 (1): 9-13. doi: 10.1016/j.amjcard.2009.03.003.
12. Chapman A.R., Shah A.S., Lee K.K., Anand A., Francis O., Adamson P., McAllister D.A., Strachan F.E., Newby D.E., Mills N.L. Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. Circulation. 2018; 137 (12): 1236-1245. doi: 10.1161/CIRCULATIONAHA.117.031806.
13. Smilowitz N.R., Gupta N., Guo Y., Berger J.S., Bangalore S. Perioperative acute myocardial infarction associated with non-cardiac surgery. European Heart Journal. 2017; 38 (31): 2409-2417. DOI: 10.1093/eurheartj/ehx313.
14. Lambrecht S., Sarkisian L., Saaby L., Poulsen T.S., Gerke O., Hosbond S., Diederichsen A.C., Thygesen K., Mickley H. Different Causes of Death in Patients with Myocardial Infarction Type 1, Type 2, and Myocardial Injury. American Journal of Medicine. 2018; 131 (5): 548-554. doi: 10.1016/j.amjmed.2017.11.043.
15. Dahhan A. Type 2 myocardial infarction: a grim diagnosis with different shades of gray. Journal of Cardiovascular Medicine (Hagerstown). 2019; 20 (8): 510-517. doi: 10.2459/JCM.0000000000000813.
16. Putot A., Jeanmichel M., Chague F., Manckoundia P., Cottin Y., Zeller M. Type 2 Myocardial Infarction: A Geriatric Population-based Model of Pathogenesis. Aging Diseases. 2020; 11 (1): 108-117. doi:10.14336/AD.2019.0405.
17. Szymanski F.M., Karpinski G., Platek A.E., Majstrak F., Hrynkiewicz-Szymanska A., Kotkowski M., Puchalski B., Filipiak K.J., Opolski G. Clinical characteristics, etiology and occurrence of type 2 acute myocardial infarction. Kardiologia Polska. 2014; 72 (4): 339-44. doi: 10.5603/KP.a2013.0284.
18. Borges F.K., Sheth T., Patel A., Marcucci M., Yung T., Langer T., Alboim C., Polanczyk C.A., Germini F., Azeredo-da-Silva A.F., Sloan E., Kaila K., Ree R., Bertoletti A., Vedovati M.C., Galzerano A., Spence J., Devereaux P.J. Accuracy of Physicians in Differentiating Type 1 and Type 2 Myocardial Infarction Based on Clinical Information. Canadian Journal of Cardiology. 2020; 2 (6): 577-584. doi: 10.1016/j.cjco.2020.07.009.
19. Putot A., Chague F., Manckoundia P., Brunel P., Beer J.C., Cottin, Y., Zeller M. Post-Infectious Myocardial Infarction: Does Percutaneous Coronary Intervention Improve Outcomes? A Propensity Score-Matched Analysis. Journal of Clinical Medicine. 2020; 9 (6), 1608. https://doi.org/10.3390/jcm9061608.
20. Januzzi J.L., Sandoval Y. The Many Faces of Type 2 Myocardial Infarction. Journal ofAmerican College of Cardiology. 2017; 70 (13): 1569-1572. doi: 10.1016/j.jacc.2017.07.784.
21. Saaby L., Poulsen T.S., Diederichsen A.C., Hosbond S., Larsen T.B., Schmidt H., Gerke O., Hallas J., Thygesen K., Mickley H. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. American Journal of Medicine. 2014; 127 (4): 295-302. doi: 10.1016/j.amjmed.2013.12.020.
22. Jogu H.R., Arora S., Vaduganathan M., Qamar A., Pandey A., Chevli P.A., Pansuriya T.H., Ahmad M.I., Dutta A., Sunkara P.R., Qureshi W., Vasu S., Upadhya B., Bhatt D.L., Januzzi J.L., Herrington D. Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clinical Cardiology. 2019; 42 (6): 592-604. doi: 10.1002/clc.23182.
23. Sulo G., Igland J., Vollset S.E., Ebbing M., Egeland G.M., Ariansen I., Tell G.S. Trends in incident acute myocardial infarction in Norway: An updated analysis to 2014 using national data from the CVDNOR project. European Journal of Preventive Cardiology. 2018; 25 (10): 1031-1039. doi: 10.1177/2047487318780033.
24. Furie N., Israel A., Gilad L., Neuman G., Assad F., Ben-Zvi I., Grossman C. Type 2 myocardial infarction in general medical wards: Clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction. Medicine (Baltimore). 2019; 98 (41): e17404. doi: 10.1097/MD.0000000000017404.
25. Melberg T., Burman R., Dickstein K. The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. International Journal of Cardiology. 2010; 139 (3): 228-33. doi: 10.1016/j.ijcard.2008.10.021.
26. Hoang H.T., Kitbalyan A.A., Lazarev P.V., Maiskov V.V., Shkolinikova E.E., Meray I.A. Type 2 myocardial infarction: clinical and demographic features, laboratory and instrumental associations. RUDN Journal of Medicine. 2018; 22 (2), 148-158. (In Russian) doi: 10.22363/2313-0245-2018-22-2-148-158
27. Urvantseva I.A., Vorobiev A.S., Suleymanov R.R., Kovalenko L.V. “Should practicing cardiologists know about type 2 myocardial infarction?” (Opinion statement of the Ugra cardiologists). Complex Issues of Cardiovascular Diseases. 2019; 8 (4): 13-15. (In Russian). https://doi.org/10.17802/2306-1278-2019-8-4-13-15.
28. Seo Y., Paik J., Shin S., Kim A., Kang S. Differential diagnostic factors of type 1 and type 2 myocardial infarction in patients with elevated cardiac troponin levels. Clin. Exp. Emerg. Med. 2020;7(3):213-219 https://doi.org/10.15441/ceem.19.049.
29. Greenslade J.H., Adikari T., Mueller C., Sandoval Y., Nestelberger T., Parsonage W., Hawkins T., Cullen L. Characteristics and occurrence of type 2 myocardial infarction in emergency department patients: a prospective study. Emergency Medicine Journal. 2018; 35 (3): 169-175. doi: 10.1136/emermed-2017-206869.
30. Averkov O.V., Barbarash O.L., Boytsov S.A., Vasilieva E.Yu., Drapkina O.M., Galyavich A.S., Gilyarov M.Yu., Zayratiants O.V., Kakturskiy L.V., Karpov Yu.A., Mishnev O.D., Nikulina N.N., Orekhov O.O., Samorodskaya I.V., Soboleva G.N., Cherkasov S.N., Shakhnovich R.M., Shilova A.S., Shlyakhto E.V., Shpektor A.V., Yavelov I.S., Yakushin S.S. Differentiated approach in diagnostics, diagnosis formulation, case management and statistical accounting of type 2 myocardial infarction (Position Paper). Russian Journal of Cardiology. 2019; (6): 7-21. (In Russian) https://doi.org/10.15829/1560-4071-2019-6-7-21
31. Stein G.Y., Herscovici G., Korenfeld R., Matetzky S., Gottlieb S., Alon D., Gevrielov-Yusim N., Iakobishvili Z., Fuchs S. Type-II myocardial infarction--patient characteristics, management and outcomes. PLoS One. 2014 Jan 2;9(1):e84285. doi: 10.1371/journal.pone.0084285..
32. Oblavatckii D.V., Boldueva S.A., Soloveva M.V., Vinnichuk S.A., Mikhailov R.R. The Frequency of Type 2 Myocardial Infarction in the Structure of Hospital Mortality According to 7-Years Data of a State University Clinic. Kardiologiia. 2020; 60 (6): 76-83. (In Russian) https://doi.org/10.18087/cardio.2020.6.n896.
33. Baron T., Hambraeus K., Sundstrom J., Erlinge D., Jernberg T., Lindahl B.; TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart. 2015;101(2):101-6. doi: 10.1136/heartjnl-2014-306093.
34. Agewall S., Beltrame J.F, Reynolds H.R, Niessner A., Rosano G., Caforio A.L., De Caterina R., Zimarino M., Roffi M., Kjeldsen K., Atar D., Kaski J.C, Sechtem U., Tornvall P; Working Group on Cardiovascular Pharmacotherapy. ESC Working Group position paper on myocardial infarction with non-obstructive coronary arteries. Eur. Heart J. 2017;38:143-153.
35. Goyal A., Gluckman T.J., Tcheng J.E. What's in a Name? The New ICD-10 (10th Revision of the International Statistical Classification of Diseases and Related Health Problems) Codes and Type 2 Myocardial Infarction. Circulation. 2017; 136 (13): 1180-1182. doi: 10.1161/CIRCULATIONAHA.117.030347.
36. McCarthy C.P., Murphy S., Rehman S., Jones-O'Connor M., Olshan D.S., Cohen J.A., Cui J., Singh A., Vaduganathan M., Januzzi J.L., Wasfy J.H. Home-Time After Discharge Among Patients With Type 2 Myocardial Infarction. Journal of American Heart Association. 2020; 9 (10): e015978. doi: 10.1161/JAHA.119.015978.
37. Gard A., Lindahl B., Hadziosmanovic N., Baron T. Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments. Journal of Clinical Medicine. 2020; 10 (1): 106. doi:10.3390/jcm10010106.
38. Sheth T., Natarajan M.K., Hsieh V., Valettas N., Rokoss M., Mehta S., Jolly S., Tandon V., Bezerra H., Devereaux P.J. Incidence of thrombosis in perioperative and non-operative myocardial infarction. British Journal of Anaesthesia. 2018; 120 (4): 725-733. doi: 10.1016/j.bja.2017.11.063.
39. Singh A., Gupta A., DeFilippis E.M., Qamar A., Biery D.W., Almarzooq Z., Collins B., Fatima A., Jackson C., Galazka P., Ramsis M., Pipilas D.C., Divakaran S., Cawley M., Hainer J., Klein J., Jarolim P., Nasir K., Januzzi J.L., Di Carli M.F., Bhatt D.L., Blankstein R. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults. Journal of American College Cardiology. 2020; 75 (9): 1003-1013. doi:10.1016/j.jacc.2019.12.052.
40. Lancellotti P., Pellikka P.A., Budts W., Chaudhry F.A., Donal E., Dulgheru R., Edvardsen T., Garbi M., Ha J.W., Kane G.C., Kreeger J., Mertens L., Pibarot P., Picano E., Ryan T., Tsutsui J.M., Varga A. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. European Heart Journal: Cardiovasc Imaging. 2016; 17 (11): 1191-1229. doi: 10.1093/ehjci/jew190.
41. Bulluck H., Dharmakumar R., Arai A.E., Berry C., Hausenloy D.J. Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. Circulation. 2018; 137 (18): 1949-1964. doi:10.1161/CIRCULATIONAHA.117.030693.
42. Lambrakis K., French J.K., Scott I.A., Briffa T., Brieger D., Farkouh M.E., White H., Chuang A.M., Tiver K., Quinn S., Kaambwa B., Horsfall M., Morton E., Chew D.P. The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. American Heart Journal. 2019; 208: 11-20. doi: 10.1016/j.ahj.2018.09.016.
43. Giustino G., Pinney S.P., Lala A., Reddy V.Y., Johnston-Cox H.A., Mechanick J.I., Halperin J.L., Fuster V. Coronavirus and Cardiovascular Disease, Myocardial Injury, andArrhythmia : JACC Focus Seminar. Journal of American College Cardiology. 2020; 76 (17): 2011-2023. doi: 10.1016/j.jacc.2020.08.059.
44. Pillai B., Trikkur S., Farooque U., Ramakrishnan D., Kakkra J.J., Kashyap G., Lalwani C., Mani A.B., Vishwanath J. Type II Myocardial Infarction: Predisposing Factors, Precipitating Elements, and Outcomes. Cureus. 2020; 12 (7): e9254. doi: 10.7759/cureus.9254.
45. Hung J., Roos J., Kadesjo J., McAllister D., Kimenai D., Shah A., Anand A., Strachan F., Fox K., Mills N., Chapman A., Holzmann M. Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. European Heart Journal. 2021; 42 (26): 2552-2561. doi:10.1093/eurheartj/ehaa375.
46. Beltrame J.F., Crea F., Camici P. Advances in coronary microvascular dysfunction. Heart Lung Circ. 2009;18:19-27. doi:10.1016/j.hlc.2008.11.002.
47. Sato R., Sakamoto K., Kaikita K., Tsujita K., Nakao K., Ozaki Y., Kimura Y., Ako J., Noguchi T., Yasuda S., Suwa S., Fujimoto K., Nakama Y., Morita T., Shimizu W., Saito Y., Hirohata Y., Morita Y., Inoue Y., Okamura A., Mano T., Hirata T., Tanabe K., Shibata Y.,Owa M., Funayama H., Kokubu N., Kozuma K., Uemura S., Toubaru T., Saku., Shigeru Ohshima K., Nishimura K., Miyamoto Y., Ogawa H., Ishihara M. Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. J. Clin. Med.2020; 9(6):1686. doi:10.3390/jcm9061686.
48. Smit M., Coetzee A.R., Lochner A. The Pathophysiology of Myocardial Ischemia and Perioperative Myocardial Infarction. Journal of Cardiothoracic and Vascular Anesthesia. 2020; 34 (9): 2501-2512. doi: 10.1053/j.jvca.2019.10.005.
49. Sykes R., Briscoe M., Krysztofiak T., Peck O., Mangion K., Berry C. Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials. Open Heart. 2021 Jun;8(1):e001633. doi: 10.1136/openhrt-2021-001633.
50. Raphael C.E., Roger V.L., Sandoval Y., Singh M., Bell M., Lerman A., Rihal C.S., Gersh B.J., Lewis B., Lennon R.J., Jaffe A.S., Gulati R. Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. Circulation. 2020; 141 (6): 454-463. doi: 10.1161/CIRCULATIONAHA.119.043100.
Review
For citations:
Kinash V.I., Vorobev A.S., Urvantseva I.A., Kovalenko L.V., Kashtalap V.V. Controversial issues of type 2 myocardial infarction patients management. Complex Issues of Cardiovascular Diseases. 2022;11(1):78-89. https://doi.org/10.17802/2306-1278-2022-11-1-78-89
Views:
1069
